DexCom, Inc. (DXCM)
Automate Your Wheel Strategy on DXCM
With Tiblio's Option Bot, you can configure your own wheel strategy including DXCM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DXCM
- Rev/Share 10.606
- Book/Share 5.7954
- PB 14.6425
- Debt/Equity 1.1397
- CurrentRatio 1.4994
- ROIC 0.0942
- MktCap 33274200020.0
- FreeCF/Share 1.4707
- PFCF 57.8481
- PE 62.0119
- Debt/Assets 0.3826
- DivYield 0
- ROE 0.2438
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | DXCM | Goldman | -- | Buy | -- | $104 | May 30, 2025 |
| Initiation | DXCM | Mizuho | -- | Outperform | -- | $85 | April 10, 2025 |
| Upgrade | DXCM | Redburn Atlantic | Neutral | Buy | $85 | $115 | Feb. 3, 2025 |
| Upgrade | DXCM | Robert W. Baird | Neutral | Outperform | $86 | $104 | Jan. 16, 2025 |
News
Here's Why You Should Add DexCom Stock to Your Portfolio Now
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM continues to raise investor optimism due to its strong product portfolio.
Read More
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Read More
Top Health & Fitness Stocks to Buy for the Wellness Boom
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
Read More
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
Read More
DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, gross margin declines and cost pressures present significant downside risks. My updated DCF analysis yields a price target of $92.90 for DXCM stock, only a 9% upside from current prices, reducing the margin of safety.
Read More
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
Published: May 08, 2025 by: MarketBeat
Sentiment: Positive
DexCom, Inc. NASDAQ: DXCM has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that underscore its sustained momentum. The company's performance, driven by strong product demand, successful innovation, and strategic market access expansion, strongly supports an ambitious trajectory for the remainder of 2025, indicating a clear path towards further solidifying its leadership in diabetes technology.
Read More
5 Best Stocks of the S&P 500 ETF in the Past Month
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.
Read More
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
Read More
Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism
Published: May 02, 2025 by: FXEmpire
Sentiment: Positive
Nasdaq jumps as Dexcom, Palantir, and ON Semi soar. Jobs report beats forecasts, easing inflation fears and driving US stock market optimism.
Read More
Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring.
Published: May 02, 2025 by: Barrons
Sentiment: Positive
Dexcom, the maker of glucose monitors for patients with diabetes, reports a strong first quarter.
Read More
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.
Read More
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.
Read More
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
Published: April 10, 2025 by: Benzinga
Sentiment: Positive
The U.S. Food and Drug Administration approved DexCom, Inc.'s DXCM Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes.
Read More
DexCom Stock Rises as Glucose Monitoring System Gets FDA Clearance
Published: April 10, 2025 by: Barrons
Sentiment: Positive
DexCom says its G7 15 Day system will land on the market in the second half of 2025.
Read More
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) time synchronously alongside Nanowear's previously FDA cleared cardiovascular biomarkers. The continuous combination of glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics offer unpre.
Read More
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Negative
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
Read More
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried
Published: March 10, 2025 by: Investors Business Daily
Sentiment: Negative
Dexcom stock plunged to a four-month low Monday after the FDA issued a warning letter tied to inspections of two facilities in the U.S. The post Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried appeared first on Investor's Business Daily.
Read More
DexCom, Inc. (DXCM) Presents at 46th Annual Raymond James Institutional Investors Brokers Conference (Transcript)
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
DexCom, Inc. (NASDAQ:DXCM ) 46th Annual Raymond James Institutional Investors Conference March 4, 2025 10:25 AM ET Company Participants Jereme Sylvain - Chief Financial Officer Matt Carey - Manager of Investor Relations Conference Call Participants Jayson Bedford - Raymond James Jayson Bedford Good morning. Welcome to the 46th Annual Raymond James Institutional Investors Conference.
Read More
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Published: February 26, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the impact of economic downturns.
Read More
Quality Key in Volatile Market, NFLX & DXCM Value Plays
Published: February 21, 2025 by: Schwab Network
Sentiment: Neutral
Friday's trading session showed weakness is possible in the current market, and Lisa Schreiber says investors need to turn to quality in a time of volatility. Lisa expects the U.S. economy to bolster strength but suggest investors bring an "umbrella' to protect their portfolios.
Read More
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
Read More
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
Published: February 14, 2025 by: Benzinga
Sentiment: Positive
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion.
Read More
DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
Read More
DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairman, President and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Jake Leach - Chief Operating Officer Conference Call Participants Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Robbie Marcus - J.P. Morgan Danielle Antalffy - UBS Travis Steed - Bank of America Joanne Wuensch - Citibank Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Capital Markets Chris …
Read More
Here's What Key Metrics Tell Us About DexCom (DXCM) Q4 Earnings
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast
Published: February 13, 2025 by: Reuters
Sentiment: Positive
Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.
Read More
About DexCom, Inc. (DXCM)
- IPO Date 2005-04-14
- Website https://www.dexcom.com
- Industry Medical - Devices
- CEO Mr. Kevin Ronald Sayer
- Employees 10200